{"id":5590,"date":"2021-11-30T21:30:58","date_gmt":"2021-11-30T21:30:58","guid":{"rendered":"https:\/\/www.cubasupport.ie\/latest\/?p=5590"},"modified":"2021-11-30T21:31:03","modified_gmt":"2021-11-30T21:31:03","slug":"cubas-bet-on-home-grown-covid-vaccines-is-paying-off","status":"publish","type":"post","link":"https:\/\/www.cubasupport.ie\/latest\/cubas-bet-on-home-grown-covid-vaccines-is-paying-off\/","title":{"rendered":"Cuba\u2019s bet on home-grown COVID vaccines is paying off"},"content":{"rendered":"\n
\"\"
A health-care worker vaccinates a woman with the Abdala jab in August.Credit: Yamil Lage\/AFP via Getty<\/figcaption><\/figure>\n\n\n\n

Preprint data show that a three-dose combo of Soberana jabs has 92.4% efficacy in clinical trials.<\/p>\n\n\n\n

When the COVID-19 pandemic began, Cuba decided not to wait on the rest of the world to develop vaccines. The United States\u2019 60-year-old economic embargo against the country, which prevents US-made products from being exported there, would make it difficult for Cuba to acquire vaccines and therapies, researchers and officials knew. \u201cIt was best, for protecting our population, to be independent,\u201d says Vicente V\u00e9rez Bencomo, director-general of the Finlay Institute of Vaccines in Havana.<\/p>\n\n\n\n

So the Finlay Institute and Cuba\u2019s other state-run biotechnology centres started developing their own COVID-19 vaccines<\/a> in the hope that at least one of them would be effective. Their bet seems to be paying off: in a 6 November preprint published on medRxiv1<\/a><\/sup>, V\u00e9rez Bencomo and his colleagues report that one of the institute\u2019s vaccines, Soberana 02, is more than 90% effective in protecting against symptomatic COVID-19 infection when used in combination with a related vaccine. Importantly, the combination seems to be effective against the highly transmissible Delta variant of the coronavirus SARS-CoV-2, which has caused surges in hospitalizations and death across the world and now accounts for nearly all COVID-19 cases in Cuba.<\/p>\n\n\n\n

As of 18 November, 89% of Cuba\u2019s population \u2014 including children as young as 2 \u2014 has received at least one dose of Soberana 02 or another Cuban vaccine called Abdala, which is produced at the Center for Genetic Engineering and Biotechnology (CIGB) in Havana. The centre reported in July<\/a> that Abdala, a three-dose vaccine, was more than 92% effective in phase III trials that included more than 48,000 participants, but the full results have not yet been published.<\/p>\n\n\n\n

Cuba\u2019s regulatory agency authorized Abdala and Soberana 02 shots for use in adults in July and August respectively, and health-care workers began immunizing children with both vaccines a few months later. The country has begun exporting the two home-grown vaccines to Venezuela, Vietnam, Iran and Nicaragua. And it has asked the World Health Organization to approve its vaccines \u2014 an important step towards making them available throughout the developing world.<\/p>\n\n\n\n

Major strides<\/h2>\n\n\n\n

In developing Soberana 02, V\u00e9rez Bencomo\u2019s group drew on its existing \u2018conjugate\u2019 vaccine technology. Finlay\u2019s conjugate vaccines take a protein or a sugar from a bacterium or virus and chemically link it to a harmless fragment of a neurotoxin protein from the tetanus bacterium. The combination elicits a stronger immune response than either component alone. Conjugate vaccines against meningitis and typhoid are used around the world, and Cuba has been immunizing children with a vaccine of this type for years.<\/p>\n\n\n\n

V\u00e9rez Bencomo\u2019s team adapted conjugate-vaccine technology to tackle COVID-19 by linking the tetanus-toxin protein to a portion, known as the receptor binding domain (RBD), of SARS-CoV-2\u2019s spike protein (the spike protein helps the virus to enter cells). After more than 14,000 people received two doses of the vaccine in a phase III trial, recipients\u2019 risk of symptomatic COVID-19 was reduced by 71%, compared with that of a placebo group of the same size \u2014 an efficacy similar to jabs made by Johnson & Johnson (J&J) in New Brunswick, New Jersey, and AstraZeneca in Cambridge, UK.<\/p>\n\n\n\n

\"Health
Health-care workers participating in a phase III trial wait to receive a Soberana 02 shot in March.Credit: Ramon Espinosa\/Reuters<\/figcaption><\/figure>\n\n\n\n

To improve on this protection, the Finlay team also gave participants a third shot. The researchers had previously tested a jab called Soberana Plus on people already sick from COVID-19 and found that it improved their immune response2<\/a><\/sup>. So they gave Soberana Plus, which is based on the RBD protein alone, to another set of 14,000 participants who had already received two Soberana 02 doses \u2014 and discovered that the third dose raised overall efficacy to 92.4%.<\/p>\n\n\n\n

V\u00e9rez Bencomo says the Finlay Institute can produce 10 million Soberana 02 doses per month. To further test the vaccine, he and his colleagues have partnered with the Pasteur Institute in Tehran to run a similar, 24,000-person trial in Iran and expect to publish those results soon.<\/p>\n\n\n\n

CIGB\u2019s Abdala vaccine is also making major strides. As with Soberana 02, the technology behind it is adapted from an existing vaccine \u2014 one for hepatitis B \u2014 that Cuba developed and has used for many years. The researchers engineered yeast cells to produce a part of the RBD different from that used in Soberana 02, and then purified the protein for use in Abdala. CIGB researcher Merardo Pujol Ferrer says that 24 million doses have been administered to 8 million people in Cuba, giving the researchers a large data set with which to track safety and efficacy. He says the team plans to publish its data later this month.<\/p>\n\n\n\n

An expanding toolbox<\/h2>\n\n\n\n

Protein-based vaccines like Soberana 02 and Abdala might have some advantages over other vaccine types<\/a>, says Craig Laferri\u00e8re, head of vaccine development at Novateur Ventures in Toronto, Canada, who has been comparing the safety and efficacy of COVID-19 jabs. Unlike the messenger RNA (mRNA) vaccines produced by Pfizer, based in New York City, and Moderna, based in Cambridge, Masschusetts, protein vaccines do not need to be kept at extremely low temperatures, making them easier to deliver to remote areas.<\/p>\n\n\n\n

And they could have fewer side effects than AstraZeneca\u2019s and J&J\u2019s vaccines, which use an adenovirus to deliver the gene for a different portion of the RBD into cells and have been linked to blood clots<\/a>. Although Finlay\u2019s medRxiv manuscript (which is not peer reviewed) does not contain extensive clinical data, Laferri\u00e8re expects Soberana 02\u2019s side effects will be minimal, because fewer than 1% of participants in the phase III trial developed a fever. Ver\u00e9z-Bencomo says further data will be published soon.<\/p>\n\n\n\n

But Laferri\u00e8re adds that there are drawbacks to the approach, too. Protein-based vaccines are made using various types of cells to synthesize gobs of protein. Soberana 02 is produced in hamster ovary cells, which is more time-consuming than some other methods for making this type of vaccine. And evidence suggests3<\/a><\/sup>\u00a0that conjugate vaccines using tetanus-toxin protein are less effective in people who have already received another vaccine of this type, such as the childhood meningitis vaccine.<\/p>\n\n\n\n

V\u00e9rez Bencomo says he has confidence in the vaccine\u2019s safety, largely because conjugate-vaccine technology has been used for decades without major problems. Having worked with it to create vaccines for use in children, the Finlay team also knew enough about dosing and side effects to leap into paediatric trials of Soberana 02, which began in June. Nearly 2 million children in Cuba have been vaccinated so far, and V\u00e9rez Bencomo says that unpublished data suggest the vaccine is safe and effective.<\/p>\n\n\n\n

\u201cI think it\u2019ll be a useful addition for the globe,\u201d says John Grabenstein, president of the vaccine consultancy Vaccine Dynamics in Easton, Maryland. \u201cEverybody\u2019s using a different tool out of the toolbox, and they pretty much are all working.\u201d He says that the Soberana 02 data look solid, but it will take time to determine how long immunity conferred by the vaccine will last.<\/p>\n\n\n\n

In the meantime, Cuba is pushing ahead with its COVID-19 vaccine-development strategy. Finlay\u2019s Soberana 01, which links the spike protein to a sugar from a meningitis-causing bacterium rather than the tetanus-toxin protein, and CIGB\u2019s Mambisa, a nasal vaccine that contains the same RBD fragment as is used in Abdala, are still in clinical trials.<\/p>\n","protected":false},"excerpt":{"rendered":"

Preprint data show that a three-dose combo of Soberana jabs has 92.4% efficacy in clinical trials. When the COVID-19 pandemic began, Cuba decided not to […]<\/a><\/p>\n","protected":false},"author":3,"featured_media":5591,"comment_status":"closed","ping_status":"closed","sticky":false,"template":"","format":"standard","meta":{"_jetpack_newsletter_access":"","_jetpack_dont_email_post_to_subs":false,"_jetpack_newsletter_tier_id":0,"_jetpack_memberships_contains_paywalled_content":false,"_jetpack_feature_clip_id":0,"_jetpack_memberships_contains_paid_content":false,"footnotes":"","jetpack_publicize_message":"","jetpack_publicize_feature_enabled":true,"jetpack_social_post_already_shared":true,"jetpack_social_options":{"image_generator_settings":{"template":"highway","default_image_id":0,"font":"","enabled":false},"version":2},"jetpack_post_was_ever_published":false},"categories":[36,43],"tags":[],"class_list":["post-5590","post","type-post","status-publish","format-standard","has-post-thumbnail","hentry","category-covid-19","category-featured"],"jetpack_publicize_connections":[],"jetpack-related-posts":[{"id":5980,"url":"https:\/\/www.cubasupport.ie\/latest\/cuba-develops-five-covid-vaccines-boast-high-vaccination-rate\/","url_meta":{"origin":5590,"position":0},"title":"Cuba Develops Five Covid Vaccines, Boast High Vaccination Rate","author":"Editorial Team","date":"March 4, 2022","format":false,"excerpt":"https:\/\/www.youtube.com\/embed\/0u6uvNp5RPQ","rel":"","context":"In "Cuba"","block_context":{"text":"Cuba","link":"https:\/\/www.cubasupport.ie\/latest\/category\/cuba\/"},"img":{"alt_text":"","src":"https:\/\/i0.wp.com\/www.cubasupport.ie\/latest\/wp-content\/uploads\/Screenshot-2022-03-04-at-14.36.36.png?fit=743%2C409&ssl=1&resize=350%2C200","width":350,"height":200,"srcset":"https:\/\/i0.wp.com\/www.cubasupport.ie\/latest\/wp-content\/uploads\/Screenshot-2022-03-04-at-14.36.36.png?fit=743%2C409&ssl=1&resize=350%2C200 1x, https:\/\/i0.wp.com\/www.cubasupport.ie\/latest\/wp-content\/uploads\/Screenshot-2022-03-04-at-14.36.36.png?fit=743%2C409&ssl=1&resize=525%2C300 1.5x, https:\/\/i0.wp.com\/www.cubasupport.ie\/latest\/wp-content\/uploads\/Screenshot-2022-03-04-at-14.36.36.png?fit=743%2C409&ssl=1&resize=700%2C400 2x"},"classes":[]},{"id":5386,"url":"https:\/\/www.cubasupport.ie\/latest\/despite-the-odds-cubas-vaccines-effective-set-for-93-rate-by-nov-2021\/","url_meta":{"origin":5590,"position":1},"title":"Despite the Odds: Cuba’s Vaccines Effective & Set for 93% Rate by Nov 2021","author":"Editorial Team","date":"October 29, 2021","format":false,"excerpt":"https:\/\/youtu.be\/KO0eahefC_w While an intense financial blockade attempts to strangle Cuba, the island nation has still performed vaccine research for over three decades -- and has produced seven COVID-19 vaccines in the last year. Cuba has few resources but has tested and approved three Covid vaccines for use on people two\u2026","rel":"","context":"In "Covid-19"","block_context":{"text":"Covid-19","link":"https:\/\/www.cubasupport.ie\/latest\/category\/cuba\/covid-19\/"},"img":{"alt_text":"","src":"https:\/\/i0.wp.com\/www.cubasupport.ie\/latest\/wp-content\/uploads\/Cuban-Vaccine-for-All.jpeg?fit=480%2C360&ssl=1&resize=350%2C200","width":350,"height":200},"classes":[]},{"id":3776,"url":"https:\/\/www.cubasupport.ie\/latest\/cubas-covid-19-vaccines-serve-the-people-not-profits\/","url_meta":{"origin":5590,"position":2},"title":"Cuba\u2019s COVID-19 Vaccines Serve the People, Not Profits","author":"Editorial Team","date":"February 22, 2021","format":false,"excerpt":"Cuba\u2019s socialist approach to developing vaccines against COVID-19 differs strikingly from that of capitalist nations of the world. Cuba\u2019s production of four vaccines is grounded in science and dedicated to saving the lives of all Cubans, and to international solidarity. The New York Times\u2019s running report on the world\u2019s vaccine\u2026","rel":"","context":"In "Featured"","block_context":{"text":"Featured","link":"https:\/\/www.cubasupport.ie\/latest\/category\/news\/featured\/"},"img":{"alt_text":"","src":"https:\/\/i0.wp.com\/www.cubasupport.ie\/latest\/wp-content\/uploads\/havana.jpeg?fit=1200%2C801&ssl=1&resize=350%2C200","width":350,"height":200,"srcset":"https:\/\/i0.wp.com\/www.cubasupport.ie\/latest\/wp-content\/uploads\/havana.jpeg?fit=1200%2C801&ssl=1&resize=350%2C200 1x, https:\/\/i0.wp.com\/www.cubasupport.ie\/latest\/wp-content\/uploads\/havana.jpeg?fit=1200%2C801&ssl=1&resize=525%2C300 1.5x, https:\/\/i0.wp.com\/www.cubasupport.ie\/latest\/wp-content\/uploads\/havana.jpeg?fit=1200%2C801&ssl=1&resize=700%2C400 2x, https:\/\/i0.wp.com\/www.cubasupport.ie\/latest\/wp-content\/uploads\/havana.jpeg?fit=1200%2C801&ssl=1&resize=1050%2C600 3x"},"classes":[]},{"id":5673,"url":"https:\/\/www.cubasupport.ie\/latest\/cuba-now-exporting-covid-vaccines\/","url_meta":{"origin":5590,"position":3},"title":"Cuba now exporting Covid vaccines","author":"Editorial Team","date":"December 18, 2021","format":false,"excerpt":"After immunising its own population, Cuba\u2019s own developed vaccines are to be marketed internationally, says ANDREAS KNOBLOCH Cuban volunteer doctors visit a slum in Caracas, Venezuela, April 2020 AS RECENTLY as August and September, Cuba had to cope with the most severe Covid outbreak to date, which pushed the health\u2026","rel":"","context":"In "Cuba"","block_context":{"text":"Cuba","link":"https:\/\/www.cubasupport.ie\/latest\/category\/cuba\/"},"img":{"alt_text":"","src":"https:\/\/i0.wp.com\/www.cubasupport.ie\/latest\/wp-content\/uploads\/10-cuban-volunteers-in-venezuela-AP_20108732454437.jpeg?fit=1180%2C585&ssl=1&resize=350%2C200","width":350,"height":200,"srcset":"https:\/\/i0.wp.com\/www.cubasupport.ie\/latest\/wp-content\/uploads\/10-cuban-volunteers-in-venezuela-AP_20108732454437.jpeg?fit=1180%2C585&ssl=1&resize=350%2C200 1x, https:\/\/i0.wp.com\/www.cubasupport.ie\/latest\/wp-content\/uploads\/10-cuban-volunteers-in-venezuela-AP_20108732454437.jpeg?fit=1180%2C585&ssl=1&resize=525%2C300 1.5x, https:\/\/i0.wp.com\/www.cubasupport.ie\/latest\/wp-content\/uploads\/10-cuban-volunteers-in-venezuela-AP_20108732454437.jpeg?fit=1180%2C585&ssl=1&resize=700%2C400 2x, https:\/\/i0.wp.com\/www.cubasupport.ie\/latest\/wp-content\/uploads\/10-cuban-volunteers-in-venezuela-AP_20108732454437.jpeg?fit=1180%2C585&ssl=1&resize=1050%2C600 3x"},"classes":[]},{"id":3377,"url":"https:\/\/www.cubasupport.ie\/latest\/under-the-radar-and-at-warp-speed-cuba-leads-latin-america-towards-affordable-covid-19-vaccines\/","url_meta":{"origin":5590,"position":4},"title":"Under the Radar and at Warp Speed Cuba Leads Latin America Towards Affordable Covid-19 Vaccines","author":"Editorial Team","date":"December 19, 2020","format":false,"excerpt":"Recently Amy\u00a0Goodman\u2019s \u201cDemocracy Now\u201d\u00a0explored\u00a0\u201cThe Case for People\u2019s Vaccines.\u201d While those interviewed by Ms. Goodman called for early and affordable access to inoculations in the Global South, no mention was made of perhaps the most promising source of such therapies. The neglected source was not only promising, but implicitly revealed the\u2026","rel":"","context":"In "Covid-19"","block_context":{"text":"Covid-19","link":"https:\/\/www.cubasupport.ie\/latest\/category\/cuba\/covid-19\/"},"img":{"alt_text":"","src":"https:\/\/i0.wp.com\/www.cubasupport.ie\/latest\/wp-content\/uploads\/IMG_6234-scaled.jpg?fit=1200%2C900&ssl=1&resize=350%2C200","width":350,"height":200,"srcset":"https:\/\/i0.wp.com\/www.cubasupport.ie\/latest\/wp-content\/uploads\/IMG_6234-scaled.jpg?fit=1200%2C900&ssl=1&resize=350%2C200 1x, https:\/\/i0.wp.com\/www.cubasupport.ie\/latest\/wp-content\/uploads\/IMG_6234-scaled.jpg?fit=1200%2C900&ssl=1&resize=525%2C300 1.5x, https:\/\/i0.wp.com\/www.cubasupport.ie\/latest\/wp-content\/uploads\/IMG_6234-scaled.jpg?fit=1200%2C900&ssl=1&resize=700%2C400 2x, https:\/\/i0.wp.com\/www.cubasupport.ie\/latest\/wp-content\/uploads\/IMG_6234-scaled.jpg?fit=1200%2C900&ssl=1&resize=1050%2C600 3x"},"classes":[]},{"id":5550,"url":"https:\/\/www.cubasupport.ie\/latest\/cuba-ships-15-million-abdala-vaccines-to-venezuela\/","url_meta":{"origin":5590,"position":5},"title":"Cuba Ships 1,5 Million Abdala Vaccines To Venezuela","author":"Editorial Team","date":"November 24, 2021","format":false,"excerpt":"\"We want to cooperate with the coronavirus immunisation of this brother country's people, who suffer the consequences of the U.S. blockade,\" Cuban scientists stated.\u00a0 On Saturday, Cuba's Center for Genetic Engineering and Biotechnology (CIGB) announced the delivery of 1,5 million Abdala COVID-19 vaccines to Venezuela. \"We want to cooperate with\u2026","rel":"","context":"In "Cuba"","block_context":{"text":"Cuba","link":"https:\/\/www.cubasupport.ie\/latest\/category\/cuba\/"},"img":{"alt_text":"","src":"https:\/\/i0.wp.com\/www.cubasupport.ie\/latest\/wp-content\/uploads\/vene_abdala.jpg_1718483346.jpg?fit=600%2C340&ssl=1&resize=350%2C200","width":350,"height":200,"srcset":"https:\/\/i0.wp.com\/www.cubasupport.ie\/latest\/wp-content\/uploads\/vene_abdala.jpg_1718483346.jpg?fit=600%2C340&ssl=1&resize=350%2C200 1x, https:\/\/i0.wp.com\/www.cubasupport.ie\/latest\/wp-content\/uploads\/vene_abdala.jpg_1718483346.jpg?fit=600%2C340&ssl=1&resize=525%2C300 1.5x"},"classes":[]}],"jetpack_likes_enabled":true,"jetpack_sharing_enabled":true,"jetpack_shortlink":"https:\/\/wp.me\/p3xdTY-1sa","jetpack_featured_media_url":"https:\/\/i0.wp.com\/www.cubasupport.ie\/latest\/wp-content\/uploads\/A-health-care-worker-vaccinates-a-woman.jpeg?fit=800%2C532&ssl=1","_links":{"self":[{"href":"https:\/\/www.cubasupport.ie\/latest\/wp-json\/wp\/v2\/posts\/5590","targetHints":{"allow":["GET"]}}],"collection":[{"href":"https:\/\/www.cubasupport.ie\/latest\/wp-json\/wp\/v2\/posts"}],"about":[{"href":"https:\/\/www.cubasupport.ie\/latest\/wp-json\/wp\/v2\/types\/post"}],"author":[{"embeddable":true,"href":"https:\/\/www.cubasupport.ie\/latest\/wp-json\/wp\/v2\/users\/3"}],"replies":[{"embeddable":true,"href":"https:\/\/www.cubasupport.ie\/latest\/wp-json\/wp\/v2\/comments?post=5590"}],"version-history":[{"count":0,"href":"https:\/\/www.cubasupport.ie\/latest\/wp-json\/wp\/v2\/posts\/5590\/revisions"}],"wp:featuredmedia":[{"embeddable":true,"href":"https:\/\/www.cubasupport.ie\/latest\/wp-json\/wp\/v2\/media\/5591"}],"wp:attachment":[{"href":"https:\/\/www.cubasupport.ie\/latest\/wp-json\/wp\/v2\/media?parent=5590"}],"wp:term":[{"taxonomy":"category","embeddable":true,"href":"https:\/\/www.cubasupport.ie\/latest\/wp-json\/wp\/v2\/categories?post=5590"},{"taxonomy":"post_tag","embeddable":true,"href":"https:\/\/www.cubasupport.ie\/latest\/wp-json\/wp\/v2\/tags?post=5590"}],"curies":[{"name":"wp","href":"https:\/\/api.w.org\/{rel}","templated":true}]}}